New research, published in BioMed Central's open access journal Stem Cell Research & Therapy, investigates the therapeutic use of human stem cells from bone marrow against acute lung injury and identifies TNF-α-induced protein 6 as a major molecular component of stem cell action.
Acute lung injury is a major complication of critically ill patients resulting in pulmonary edema, hypoxia and, in the worst cases, organ failure. Consequently up to 40% of all sufferers die because their bodies' immune systems overreact in an attempt to repair the original lung damage.
Researchers based in Louisiana showed that therapy with human multipotent stromal cells (hMSC) isolated from bone marrow was able to significantly reduce acute lung injury in mice after 48 hours. At 24 hours the therapy could be seen to be working, reducing the amount of pulmonary edema and protein in the lungs. While injury increased the number of white blood cells (neutrophils) ten fold, this could be reduced by treatment with hMSC.
When the researchers looked in more detail, they found that hMSC treatment reduced over half of the inflammatory proteins tested, including IL-1α, Il-1β, IL-6 and RANTES. hMSC treatment also increased the amount of the anti-inflammatory proteins TNF-α-induced protein 6 (TSG6) and Interleukin 1 receptor antagonist (IL-1RN).
Dr Sullivan, from the Center for Stem Cell Research and Regenerative Medicine at Tulane University School of Medicine, said, "Our research reveals an important mechanism behind the anti-inflammatory activity of stem cells in lung injury because blocking the activity of TSG6 using siRNA prevented most of the anti-inflammatory effects of hMSC.
"Stem cell therapy shows great promise in the treatment of acute and life threatening conditions, such as acute lung injury and acute respiratory distress syndrome. Understanding the mechanisms by which hMSC dampen inflammation will likely provide strategies to improve the therapeutic potential of hMSCs for treatment of lung injury. Since it is a simple procedure to collect stem cells from bone marrow, we hope that our research paves the way forward into clinical trials."
Media Contact
Dr Hilary Glover
Scientific Press Officer, BioMed Central
Tel: +44 (0) 20 3192 2370
Email: hilary.glover@biomedcentral.com
Notes to Editors
1. The Human multipotent stromal cells attenuate lipopolysaccharide-induced acute lung injury in mice via secretion of tumor necrosis factor--induced protein 6
Svitlana Danchuk, Joni H Ylostalo, Fokhrul Hossain, Randy Sorge, Austin Ramsey, Ryan W Bonvillain, Joseph A Lasky, Bruce A Bunnell, David A Welsh, Darwin J Prockop and Deborah E Sullivan
Stem Cell Research & Therapy (in Press)
Please name the journal in any story you write. If you are writing for the web, please link to the article. All articles are available free of charge, according to BioMed Central's open access policy.
Article citation and URL available on request at press@biomedcentral.com on the day of publication.
2. Stem Cell Research & Therapy is an international peer-reviewed journal, which publishes original open access research articles of outstanding quality. Stem Cell Research & Therapy is the major forum for translational research into stem cell therapies and has a special emphasis on basic, translational, and clinical research into stem cell therapeutics, including animal models, and clinical trials.
3. BioMed Central (http://www.biomedcentral.com/) is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector.
Journal
Stem Cell Research & Therapy